Completed PHASE2 INTERVENTIONAL 1-arm NCT01540071

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

A Phase II Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Sponsor: Io Therapeutics

Conditions Castration Resistant Prostate Cancer

Interventions NRX 194204

Updated 9 times since 2017 Last updated: Apr 23, 2021 Started: Aug 31, 2011 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Castration Resistant Prostate Cancer and is currently completed. Io Therapeutics leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jun 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Jun 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Io Therapeutics

Data source: Io Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fountain Valley, United States